Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis (JAKARTA)

July 20, 2026 updated by: Bristol-Myers Squibb

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study of SAR302503 in Patients With Intermediate-2 or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly

Primary Objective:

  • To evaluate the efficacy of daily oral doses of 400 mg or 500 mg of SAR302503 (Investigational Medicinal Product, IMP) compared to placebo in the reduction of spleen volume as determined by magnetic resonance imaging (MRI) (or computed tomography scan in patients with contraindications for MRI).

Secondary Objectives:

  • To evaluate the effect on Myelofibrosis (MF)-associated symptoms (key MF symptoms) as measured by the modified Myelofibrosis Symptom Assessment Form (MFSAF) diary.
  • To evaluate the Overall Survival of patients treated with either 400 mg/day or 500 mg/day of IMP as compared to placebo.
  • To evaluate the Progression Free Survival of patients treated with either 400 mg/day or 500 mg/day of IMP as compared to placebo.
  • To evaluate the durability of splenic response.
  • To evaluate the safety of IMP.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Terminated

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

The expected duration of a patient's treatment in this study is approximately 8 months, based on a maximum 28-day screening period, followed by a ≥6-month (6-cycle) treatment period, and an End Of Treatment (EOT) visit, which should be performed at least 30 days following the last administration of IMP or placebo.

Patients who continue to benefit clinically will be allowed to remain on IMP or placebo beyond the 6-month treatment period until the occurrence of disease progression or unacceptable toxicity.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
289

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Australia
      • Box Hill, Australia, 3128
        • Investigational Site Number 036001
      • Herston, Australia, 4029
        • Investigational Site Number 036005
      • Randwick, Australia, 2031
        • Investigational Site Number 036003
      • Tweed Heads, Australia, 2485
        • Investigational Site Number 036004
      • Wodonga, Australia, 3690
        • Investigational Site Number 036002
  • Austria
      • Vienna, Austria, 1090
        • Investigational Site Number 040001
  • Belgium
      • Antwerp, Belgium, 2060
        • Investigational Site Number 056003
      • Leuven, Belgium, 3000
        • Investigational Site Number 056001
  • Brazil
      • Jaú, Brazil, 17210-120
        • Investigational Site Number 076002
      • Porto Alegre, Brazil, 90110-270
        • Investigational Site Number 076004
      • Rio de Janeiro, Brazil, 20230-130
        • Investigational Site Number 076001
  • Canada
      • Montreal, Canada, H1T 2M4
        • Investigational Site Number 124001
      • Montreal, Canada, H2W 1S6
        • Investigational Site Number 124003
      • Saint John, Canada, E2L 4L2
        • Investigational Site Number 124002
  • France
      • Marseille, France, 13273
        • Investigational Site Number 250006
      • Nantes, France, 44093
        • Investigational Site Number 250005
      • Nîmes, France, 30029
        • Investigational Site Number 250004
      • Pierre-Bénite, France, 69495
        • Investigational Site Number 250002
      • Poitiers, France, 86000
        • Investigational Site Number 250007
      • Toulouse, France, 31000
        • Investigational Site Number 250003
      • Villejuif, France, 94805
        • Investigational Site Number 250001
  • Germany
      • Aachen, Germany, 52074
        • Investigational Site Number 276006
      • Bonn, Germany, 53127
        • Investigational Site Number 276007
      • Dresden, Germany, 01307
        • Investigational Site Number 276008
      • Mannheim, Germany, 68167
        • Investigational Site Number 276001
  • Hungary
      • Budapest, Hungary, 1097
        • Investigational Site Number 348002
      • Debrecen, Hungary, 4032
        • Investigational Site Number 348001
      • Győr, Hungary, 9023
        • Investigational Site Number 348007
      • Kecskemét, Hungary, 6000
        • Investigational Site Number 348006
      • Miskolc, Hungary, 3529
        • Investigational Site Number 348003
  • Ireland
      • Dublin, Ireland, DUBLIN 8
        • Investigational Site Number 372002
      • Galway, Ireland
        • Investigational Site Number 372001
  • Israel
      • Haifa, Israel, 31048
        • Investigational Site Number 376003
      • Tel Litwinsky, Israel, 52621
        • Investigational Site Number 376002
  • Italy
      • Bergamo, Italy, 24127
        • Investigational Site Number 380002
      • Bologna, Italy, 40138
        • Investigational Site Number 380007
      • Florence, Italy, 50134
        • Investigational Site Number 380004
      • Pavia, Italy, 27100
        • Investigational Site Number 380001
      • Pavia, Italy, 27100
        • Investigational Site Number 380006
      • Varese, Italy, 21100
        • Investigational Site Number 380003
  • Lithuania
      • Kaunas, Lithuania, LT-50009
        • Investigational Site Number 440001
      • Klaipėda, Lithuania, LT-92288
        • Investigational Site Number 440002
  • Mexico
      • Querétaro, Mexico, 76000
        • Investigational Site Number 484001
  • Poland
      • Brzozów, Poland, 36-200
        • Investigational Site Number 616005
      • Gdansk, Poland, 80-952
        • Investigational Site Number 616002
      • Lodz, Poland, 93-510
        • Investigational Site Number 616006
      • Warsaw, Poland, 02-106
        • Investigational Site Number 616010
      • Wroclaw, Poland, 50-367
        • Investigational Site Number 616003
  • Portugal
      • Coimbra, Portugal, 3000-075
        • Investigational Site Number 620005
      • Lisbon, Portugal, 1169-050
        • Investigational Site Number 620004
      • Lisbon, Portugal, 1649-035
        • Investigational Site Number 620001
      • Porto, Portugal, 4200-072
        • Investigational Site Number 620003
  • Romania
      • Brasov, Romania
        • Investigational Site Number 642003
      • Bucharest, Romania, 022328
        • Investigational Site Number 642004
      • Bucharest, Romania, 030171
        • Investigational Site Number 642002
      • Bucharest, Romania
        • Investigational Site Number 642006
      • Timișoara, Romania
        • Investigational Site Number 642001
  • Russia
      • Moscow, Russia, 125167
        • Investigational Site Number 643009
      • Moscow, Russia, 125284
        • Investigational Site Number 643001
      • Nizhny Novgorod, Russia, 603126
        • Investigational Site Number 643010
      • Petrozavodsk, Russia, 185019
        • Investigational Site Number 643008
      • Saint Petersburg, Russia, 191024
        • Investigational Site Number 643005
      • Saint Petersburg, Russia, 197341
        • Investigational Site Number 643004
      • Volgograd, Russia, 400138
        • Investigational Site Number 643007
  • Singapore
      • Singapore, Singapore, 119228
        • Investigational Site Number 702002
      • Singapore, Singapore, 169608
        • Investigational Site Number 702001
  • South Africa
      • Johannesburg, South Africa, 2013
        • Investigational Site Number 710003
      • Parktown, South Africa, 2193
        • Investigational Site Number 710002
  • South Korea
      • Bundang-Gu, South Korea, 463-707
        • Investigational Site Number 410002
      • Seoul, South Korea, 110-744
        • Investigational Site Number 410004
      • Seoul, South Korea, 120-752
        • Investigational Site Number 410003
      • Seoul, South Korea, 135-710
        • Investigational Site Number 410001
      • Seoul, South Korea, 137-701
        • Investigational Site Number 410005
      • Seoul, South Korea, 138-878
        • Investigational Site Number 410006
      • Seoul, South Korea
        • Investigational Site Number 410007
  • Spain
      • Barcelona, Spain, 08036
        • Investigational Site Number 724001
      • Madrid, Spain, 28046
        • Investigational Site Number 724002
  • Sweden
      • Stockholm, Sweden, 14186
        • Investigational Site Number 752001
      • Uddevalla, Sweden, 451 80
        • Investigational Site Number 752002
  • Taiwan
      • Changhua, Taiwan, 500
        • Investigational Site Number 158002
      • Kaohsiung City, Taiwan, 833
        • Investigational Site Number 158003
      • Taipei, Taiwan, 112
        • Investigational Site Number 158001
  • United Kingdom
      • Belfast, United Kingdom, BT9 7AB
        • Investigational Site Number 826006
      • Birmingham, United Kingdom, B9 5SS
        • Investigational Site Number 826003
      • Glasgow, United Kingdom, G12 0YN
        • Investigational Site Number 826002
      • Leeds, United Kingdom, LS9 7TF
        • Investigational Site Number 826004
      • London, United Kingdom, SE1 9RT
        • Investigational Site Number 826001
      • London, United Kingdom, W12 0HS
        • Investigational Site Number 826005
      • Manchester, United Kingdom, M20 4BX
        • Investigational Site Number 826007
      • Newcastle upon Tyne, United Kingdom, NE7 7DN
        • Investigational Site Number 826008
      • Oxford, United Kingdom, OX3 7LJ
        • Investigational Site Number 826009
      • Southampton, United Kingdom, SO16 6YD
        • Investigational Site Number 826010
  • United States
    • Arizona
      • Scottsdale, Arizona, United States, 85259-5499
        • Investigational Site Number 840014
    • California
      • La Jolla, California, United States, 92093
        • Investigational Site Number 840001
      • La Jolla, California, United States, 92093
        • Investigational Site Number 840012
      • Los Angeles, California, United States, 90033
        • Investigational Site Number 840006
    • Louisiana
      • Baton Rouge, Louisiana, United States, 70808
        • Investigational Site Number 840013
    • Minnesota
      • Rochester, Minnesota, United States, 55905
        • Investigational Site Number 840008
    • New Jersey
      • Newark, New Jersey, United States, 07112
        • Investigational Site Number 840009
    • Ohio
      • Canton, Ohio, United States, 44718
        • Investigational Site Number 840002
    • Texas
      • Houston, Texas, United States, 77030
        • Investigational Site Number 840004

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion criteria:

  • Diagnosis of Primary Myelofibrosis (MF) or Post-Polycythemia Vera MF or Post-Essential Thrombocythemia MF, according to the 2008 World Health Organization and International Working Group of Myelofibrosis Research and Treatment (IWG-MRT) criteria.
  • MF classified as high-risk or intermediate-risk level 2, as defined by modified IWG-MRT criteria (IPSS) (according to Cervantes F. et. al.; at screening).
  • Enlarged spleen, palpable at least 5 cm below costal margin.
  • At least 18 years of age.
  • Eastern Cooperative Oncology Group performance status of 0, 1, or 2 at study entry.
  • The following laboratory values within 14 days prior to the initiation of IMP or placebo:
  • Absolute Neutrophil Count (ANC) ≥1.0 x 10exp9/L
  • Platelet count ≥50 x 10exp9/L
  • Serum creatinine ≤1.5 x Upper Limit of Normal (ULN)
  • Serum amylase and lipase ≤1.5 x ULN

Exclusion criteria:

  • Splenectomy.
  • Any chemotherapy (eg, hydroxyurea), immunomodulatory drug therapy (eg, thalidomide, interferon-alpha), Anagrelide, immunosuppressive therapy, corticosteroids >10 mg/day prednisone or equivalent, or growth factor treatment (eg, erythropoietin), or hormones (eg, androgens, danazol) within 14 days prior to initiation of IMP or placebo; darbepoetin use within 28 days prior to initiation of IMP or placebo. Patients who have had exposure to hydroxyurea (eg, hydrea) in the past may be enrolled into the study as long as it has not been administered within 14 days prior to initiation of IMP or placebo.
  • Major surgery within 28 days or radiation within 6 months prior to initiation of IMP or placebo.
  • Prior treatment with a Janus Kinase 2 (JAK2) inhibitor.
  • Known active (acute or chronic) Hepatitis A, B, or C; and hepatitis B and C carriers
  • AST or ALT ≥2.5 x ULN
  • Total Bilirubin:
  • Exclude if ≥3.0 x ULN
  • Patients with total bilirubin between 1.5-3.0 x ULN must be excluded if the direct bilirubin fraction is ≥25% of the total
  • Prior history of chronic liver disease (eg, chronic alcoholic liver disease, autoimmune hepatitis, sclerosing cholangitis, primary biliary cirrhosis, hemachromatosis, non-alcoholic steatohepatitis [NASH])

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Placebo Comparator: Placebo comparator
once daily X 28 days, orally, empty stomach, approximately same time each day
Drug: Placebo

Pharmaceutical form:capsule

Route of administration: oral
Experimental: SAR302503 400 mg
once daily X 28 days, orally, empty stomach, approximately same time each day
Drug: SAR302503

Pharmaceutical form:capsule

Route of administration: oral
Experimental: SAR302503 500 mg
once daily X 28 days, orally, empty stomach, approximately same time each day
Drug: SAR302503

Pharmaceutical form:capsule

Route of administration: oral

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Response Rate (RR): Percentage of Participants Who Had a >=35% Reduction From Baseline in Volume of Spleen Size at The End Cycle 6
Time Frame: Baseline, Week 24
Spleen volume was determined by magnetic resonance imaging (MRI) (or computed tomography scan in participants with contraindications for MRI) at baseline and at the end of cycle 6 with a confirmatory scan approximately 4 weeks after the end of Cycle 6. The MRI or CT imaging results reviewed in a blinded manner by an Independent Review Committee (IRC). Analysis was performed on intent-to-treat (ITT) population defined as all randomized participants who signed informed consent form (ICF).
Baseline, Week 24

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Symptom Response Rate (SRR): Percentage of Participants With >=50% Reduction From Baseline in the Total Symptom Score at End of Cycle 6
Time Frame: Baseline, Week 24
Total symptom score is the averaged value of the daily scores for each of 6 key Myelofibrosis (MF) associated Symptom items (night sweats, pruritus, abdominal discomfort, early satiety [filling up quickly when you eat], pain under ribs on left side, and bone or muscle pain), each item measured on a scale from 0 (absent) to 10 (worst imaginable). A higher score indicates worse symptoms. Analysis was performed on ITT population. Number of participants analysed= participants with available data at end of cycle 6.
Baseline, Week 24
Percentage of Participants Who Had >=25% Reduction From Baseline in Volume of Spleen Size at End of Cycle 6
Time Frame: Baseline, Week 24
Spleen volume was determined by magnetic resonance imaging (MRI) (or computed tomography scan in subjects with contraindications for MRI) at baseline and at the end of cycle 6 with a confirmatory scan approximately 4 weeks after the end of Cycle 6. Analysis was performed on ITT population.
Baseline, Week 24

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Bristol-Myers Squibb

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: Clinical Sciences & Operations, Sanofi

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
December 31, 2011

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
June 30, 2014

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
June 30, 2014

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
September 16, 2011

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 20, 2011

First Posted (Estimated)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
September 21, 2011

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
August 11, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 20, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
July 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • EFC12153
  • 2011-001897-25 (EudraCT Number)
  • U1111-1121-7170 (Other Identifier: UTN)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings